MarginsXMarginsX
Home › Markets › Health Care › CRDL

Cardiol Therapeutics Inc. Class A Common Shares (CRDL)

CRDL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.9798
-2.02% on the day
Market cap
$125.1M
Micro cap
Revenue · 2021
$55K
No prior year to compare
Net income · 2021
-$22.2M
-40170.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2021-12-31, https://www.sec.gov/Archives/edgar/data/1702123/000110465924041952/0001104659-24-041952-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2021-12-31. Converted from CAD at 1.4258 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerCRDL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001702123
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inON
Canadian listingTSX: CRDL

Financials · 2021

LineValue
Revenue$55K
Net income-$22.2M
Operating income-$27.1M
Net margin-40170.4%
Operating margin-49091.9%
Revenue growthNo prior-year revenue to compare
Cash$58.8M
Total assets$61.6M
P/E (computed)Net income was not positive
P/S (computed)2264.9×

Reported in CAD; shown in US dollars.

Warning signs

Cash runway
10.8 months
21.4M CAD cash at December 31, 2025
Share count, 1 year
+21.4%
2024-12-31 to 2025-12-31 · +56.5% over 3 years
Going-concern doubt
No
40-F filed March 31, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.40-F 2026-03-31
Cash and burn21.4M CAD cash; operating cash flow -6.0M CAD a quarter.Report 2025-12-31
Shares outstanding100,257,009 (2025-12-31); 82,608,992 a year earlier; 64,042,536 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO Canada LLP, Oakville, CanadaPCAOB Form AP 2026-04-14
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-33.8M CAD-23.9M CAD21.4M CADNo debt tagsNeeds four quarters40-F 2026-03-31
FY 2024
2024-12-31
Not filed-36.7M CAD-25.1M CAD30.6M CADNo debt tagsNeeds four quarters40-F 2026-03-31
FY 2023
2023-12-31
Not filed-28.1M CAD-25.2M CAD34.9M CADNo debt tagsNeeds four quarters40-F 2025-03-31
FY 2022
2022-12-31
Not filed-30.9M CAD-27.2M CAD59.5M CADNo debt tagsNeeds four quarters20-F 2024-04-01
FY 2021
2021-12-31
79K CAD-31.6M CAD-23.5M CAD83.9M CADNo debt tags79K CAD20-F 2024-04-01
FY 2020
2020-12-31
Not filed-20.6M CAD-9.1M CAD14.0M CADNo debt tagsNeeds four quarters20-F 2023-03-29

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in CAD.

Key SEC documents

DocumentFormFiled
Latest annual report40-F2026-03-31
Latest quarterly / interim
FORM 6-K
6-K2026-11-12

Source: SEC EDGAR submissions feed, 189 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.5%
1 month-16.7%
3 months-41.5%
Year to date+4.8%
1 year-2.0%
From 52-week high-56.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ENGNenGene Therapeutics Inc.$1.89-21.58%$126.7M
LENZLENZ Therapeutics Inc.$3.82-7.51%$120.0M
CMPXCompass Therapeutics Inc.$0.6615-14.51%$119.1M
FATEFate Therapeutics Inc.$1.14-10.94%$138.6M
ARMPArmata Pharmaceuticals Inc.$2.99-22.74%$111.2M
TARAProtara Therapeutics Inc.$2.38-5.93%$146.5M
HUMAHumacyte Inc.$0.5403-3.24%$150.1M
ZURAZura Bio Limited$1.08-12.90%$104.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier